I'd expect better than 20% Rev growth at this stage considering the R&D, Sales and Capex spend, which is $70m+ in total. The issue will be whether they plan to continue at this level.
The cash-debt situation is worse than that because they have a $35m payment to make on acquisitions in current liabilities.